Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

BACKGROUND: Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded significant increases in PFS and OS for melanoma. However, at present, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Daud, Adil, Gill, Japinder, Kamra, Sheily, Chen, Lei, Ahuja, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209913/
https://www.ncbi.nlm.nih.gov/pubmed/28052762
http://dx.doi.org/10.1186/s13045-016-0369-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209913/
https://www.ncbi.nlm.nih.gov/pubmed/28052762
http://dx.doi.org/10.1186/s13045-016-0369-8

Ejemplares similares